259 related articles for article (PubMed ID: 22240132)
1. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
[TBL] [Abstract][Full Text] [Related]
3. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
Custodis F; Baumhäkel M; Schlimmer N; List F; Gensch C; Böhm M; Laufs U
Circulation; 2008 May; 117(18):2377-87. PubMed ID: 18443241
[TBL] [Abstract][Full Text] [Related]
4. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
Zeng Y; Li C; Guan M; Zheng Z; Li J; Xu W; Wang L; He F; Xue Y
Cardiovasc Diabetol; 2014 Feb; 13():32. PubMed ID: 24490809
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
6. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
7. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
Kim YS; Oh SH; Park KS; No H; Oh BJ; Kim SK; Jung HS; Kim JH; Lee MS; Lee MK; Kim KW
Pancreas; 2011 Aug; 40(6):855-60. PubMed ID: 21747318
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
Li B; Luo YR; Zhang Q; Fu SH; Chen YD; Tian JW; Guo Y
Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection.
Murohara T
J Am Coll Cardiol; 2012 Jan; 59(3):277-9. PubMed ID: 22240133
[No Abstract] [Full Text] [Related]
11. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
Lu HY; Huang CY; Shih CM; Chang WH; Tsai CS; Lin FY; Shih CC
PLoS One; 2015; 10(4):e0121077. PubMed ID: 25876091
[TBL] [Abstract][Full Text] [Related]
14. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.
Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
Metabolism; 2014 Sep; 63(9):1141-8. PubMed ID: 25034387
[TBL] [Abstract][Full Text] [Related]
15. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
[TBL] [Abstract][Full Text] [Related]
16. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
Pei Z
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
[TBL] [Abstract][Full Text] [Related]
17. Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
Lenski M; Kazakov A; Marx N; Böhm M; Laufs U
J Mol Cell Cardiol; 2011 Dec; 51(6):906-18. PubMed ID: 21871459
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor.
Abd El Motteleb DM; Elshazly SM
Eur J Pharmacol; 2013 Nov; 720(1-3):158-65. PubMed ID: 24238127
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
20. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.
Ishibashi Y; Matsui T; Takeuchi M; Yamagishi S
Horm Metab Res; 2011 Sep; 43(10):731-4. PubMed ID: 21932180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
